Physician

Michael Keiichi Fujinaka, MD

According to 2025 Medicare claims, Michael Fujinaka, MD (NPI: 1598051278) practices pain management in the Arlington-Alexandria-Reston, VA-WV market, with the plurality of this provider's patient population coming from Fairfax, VA. This provider's primary affiliated billing organization is LIV SPECIALTY CARE CT PC (NPI: 1275314148; TIN: 933748150) and primary practice location at 20164-1896.

Fujinaka's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 167 traditional Medicare patients, billed 118,377 HCPCS/CPT codes, and received $1,604,064 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). 2022 Part D data shows 15 prescription claims totaling $599 in drug costs. Open Payments data shows 1 records totaling $25. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $23,134 and ending at $1,604,064. Concurrently, Part D prescription costs started with an early spike, then settled into a lower baseline, moving from $4,257 to $599. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$802K$1.6M2016 Medicare payment: $23,134 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $41,219 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $29,191 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $108,270 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $195,981 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $33,501 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $19,838 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $456,957 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $1,604,064 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
2016128261$23,134
2017252691$41,219
2018177379$29,191
2019149772$108,270
20202933,235$195,981
2021116322$33,501
2022102167$19,838
20234729,390$456,957
2024167118,377$1,604,064

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$9.9K$20K2016 Drug cost: $4,257 (USD; Tot_Drug_Cst)2017 Drug cost: $19,722 (USD; Tot_Drug_Cst)2018 Drug cost: $14,653 (USD; Tot_Drug_Cst)2019 Drug cost: $7,572 (USD; Tot_Drug_Cst)2020 Drug cost: $4,663 (USD; Tot_Drug_Cst)2021 Drug cost: $293 (USD; Tot_Drug_Cst)2022 Drug cost: $599 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015N/RN/RN/R
20163159$4,257
201799270$19,722
201851155$14,653
201934106$7,572
202044114$4,663
2021N/R11$293
2022N/R15$599
2023N/RN/RN/R
2024N/RN/RN/R

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
96413Administration of chemotherapy into vein, 1 hour or less4287$100
96401Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle1729$58
96365Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less57142$50
96372Injection of drug or substance under skin or into muscle33107$12
J0174Injection, lecanemab-irmb, 1 mg1637,810$1

Top 5 Part D drugs in 2024

By total drug costs.

No connected Part D drug-level records for 2024.

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.1$25Takeda Pharmaceuticals U.S.A., Inc.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Michael Keiichi Fujinaka, MD?

Tedicare shows public-source Medicare data for Michael Keiichi Fujinaka, MD (NPI 1598051278), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Michael Keiichi Fujinaka, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Michael Keiichi Fujinaka, MD?

Michael Keiichi Fujinaka, MD is linked to LIV SPECIALTY CARE CT PC (billing NPI 1275314148) in the available physician profile data.

Does Michael Keiichi Fujinaka, MD have Open Payments data?

Michael Keiichi Fujinaka, MD has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.